Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ARCT Stock Forecast 2025-2026
$7.13
Current Price
$202.58M
Market Cap
Buy 8
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to ARCT Price Targets
+909.8%
To High Target of $72.00
+201.5%
To Median Target of $21.50
+26.2%
To Low Target of $9.00
ARCT Price Momentum
+5.0%
1 Week Change
-18.2%
1 Month Change
-62.7%
1 Year Change
-58.0%
Year-to-Date Change
-70.5%
From 52W High of $24.17
+21.9%
From 52W Low of $5.85
📊 TOP ANALYST CALLS
Did ARCT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Arcturus is one of their latest high-conviction picks.
Latest ARCT Stock Price Targets & Analyst Predictions
Based on our analysis of 21 Wall Street analysts, ARCT has a bullish consensus with a median price target of $21.50 (ranging from $9.00 to $72.00). The overall analyst rating is N/A (N/A/10). Currently trading at $7.13, the median forecast implies a 201.5% upside. This outlook is supported by 8 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 909.8% upside. Conversely, the most conservative target is provided by Yigal Nochomovitz at Citigroup, suggesting a 26.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARCT Analyst Ratings
8
Buy
3
Hold
0
Sell
ARCT Price Target Range
Low
$9.00
Average
$21.50
High
$72.00
Current: $7.13
Latest ARCT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARCT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2025 | Citigroup | Yigal Nochomovitz | Neutral | Maintains | $9.00 |
| Nov 11, 2025 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $72.00 |
| Nov 11, 2025 | HC Wainwright & Co. | Andrew S. Fein | Neutral | Maintains | $9.00 |
| Oct 24, 2025 | HC Wainwright & Co. | Andrew S. Fein | Neutral | Downgrade | $12.00 |
| Oct 23, 2025 | Citigroup | Yigal Nochomovitz | Neutral | Downgrade | $12.00 |
| Oct 23, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $20.00 |
| Oct 23, 2025 | Guggenheim | Seamus Fernandez | Neutral | Downgrade | $N/A |
| Oct 22, 2025 | BTIG | Thomas Shrader | Buy | Maintains | $23.00 |
| Oct 22, 2025 | Guggenheim | Seamus Fernandez | Neutral | Downgrade | $N/A |
| Sep 4, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Assumes | $60.00 |
| Aug 22, 2025 | Leerink Partners | Lili Nsongo | Outperform | Maintains | $54.00 |
| Aug 12, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $42.00 |
| Aug 12, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $49.00 |
| Jul 2, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $35.00 |
| May 28, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Initiates | $32.00 |
| May 14, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $45.00 |
| May 13, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $66.00 |
| Apr 10, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $60.00 |
| Mar 10, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $68.00 |
| Mar 7, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $50.00 |
Arcturus Therapeutics Holdings Inc. (ARCT) Competitors
The following stocks are similar to Arcturus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ARCT
Arcturus Therapeutics
mkt cap
202.58M
Arcturus Therapeutics Holdings Inc. (ARCT) Financial Data
Arcturus Therapeutics Holdings Inc. has a market capitalization of $202.58M with a P/E ratio of 10.1x. The company generates $97.60M in trailing twelve-month revenue with a -68.3% profit margin.
Revenue growth is -58.8% quarter-over-quarter, while maintaining an operating margin of -96.3% and return on equity of -27.4%.
Valuation Metrics
Market Cap
$202.58M
Enterprise Value
$48.21M
P/E Ratio
10.1x
PEG Ratio
0.1x
Price/Sales
2.1x
Growth & Margins
Revenue Growth (YoY)
-58.8%
Gross Margin
N/A
Operating Margin
-96.3%
Net Margin
-68.3%
EPS Growth
-63.5%
Financial Health
Cash/Price Ratio
+89.0%
Current Ratio
7.9x
Debt/Equity
11.6x
ROE
-27.4%
ROA
-15.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Arcturus Therapeutics Holdings Inc. (ARCT) Business Model
About Arcturus Therapeutics Holdings Inc.
What They Do
Develops RNA-based therapeutics for rare diseases.
Business Model
The company generates revenue through the development and commercialization of RNA medicines, primarily utilizing its proprietary LUNAR® platform. By forming collaborations with global pharmaceutical companies, Arcturus accelerates the development of its therapeutic candidates while also sharing expertise and resources, which can lead to potential milestone payments and royalties.
Additional Information
Arcturus operates in the biotechnology sector, focusing on innovative solutions for unmet clinical needs. Its approach aims to transform traditional therapies, positioning the company as a significant player in the advancement of precision medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
174
CEO
Mr. Joseph E. Payne M.Sc.
Country
United States
IPO Year
2012
Website
arcturusrx.comArcturus Therapeutics Holdings Inc. (ARCT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.
Dec 01, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Arcturus Therapeutics' stock fell 59% following mixed interim results from the phase II study of its inhaled cystic fibrosis therapy, ARCT-032.
Why It Matters
Arcturus Therapeutics' 59% stock drop signals investor concern over the viability of ARCT-032, impacting future funding, partnerships, and overall market confidence in the company.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Arcturus Therapeutics (Nasdaq: ARCT) will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 12:30 p.m. ET, focusing on mRNA therapies and vaccines.
Why It Matters
Arcturus Therapeutics' participation in a major healthcare conference highlights its ongoing developments in mRNA therapeutics, potentially influencing investor interest and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Arcturus Therapeutics Holdings Inc. (ARCT) will hold its Q3 2025 earnings call on November 10, 2025, at 4:30 PM EST, featuring key executives and analysts from various firms.
Why It Matters
The earnings call provides insights into Arcturus Therapeutics' financial health and future prospects, influencing stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Edelson Lechtzin LLP is investigating Arcturus Therapeutics (NASDAQ: ARCT) for potential violations of federal securities laws related to misleading business information.
Why It Matters
Edelson Lechtzin LLP's investigation into Arcturus for possible securities law violations raises concerns about transparency and credibility, potentially impacting stock value and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Arcturus Therapeutics (ARCT) reported a quarterly loss of $0.49 per share, better than the expected loss of $1.25, but worse than a loss of $0.26 per share from the previous year.
Why It Matters
Arcturus Therapeutics' smaller-than-expected loss suggests improving financial health, potentially boosting investor confidence and stock performance. Year-over-year loss increase may raise concerns.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
27 days ago
Quick Summary
Arcturus Therapeutics (Nasdaq: ARCT) reported Q3 2025 financial results and shared initial findings of ARCT-032 clinical activity for cystic fibrosis with the community.
Why It Matters
Arcturus Therapeutics' Q3 financial results and clinical updates on ARCT-032 signal progress in rare disease and vaccine development, potentially influencing stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ARCT Stock
What is Arcturus Therapeutics Holdings Inc.'s (ARCT) stock forecast for 2026?
Based on our analysis of 21 Wall Street analysts, Arcturus Therapeutics Holdings Inc. (ARCT) has a median price target of $21.50. The highest price target is $72.00 and the lowest is $9.00.
Is ARCT stock a good investment in 2026?
According to current analyst ratings, ARCT has 8 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.13. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ARCT stock?
Wall Street analysts predict ARCT stock could reach $21.50 in the next 12 months. This represents a 201.5% increase from the current price of $7.13. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Arcturus Therapeutics Holdings Inc.'s business model?
The company generates revenue through the development and commercialization of RNA medicines, primarily utilizing its proprietary LUNAR® platform. By forming collaborations with global pharmaceutical companies, Arcturus accelerates the development of its therapeutic candidates while also sharing expertise and resources, which can lead to potential milestone payments and royalties.
What is the highest forecasted price for ARCT Arcturus Therapeutics Holdings Inc.?
The highest price target for ARCT is $72.00 from Yasmeen Rahimi at Piper Sandler, which represents a 909.8% increase from the current price of $7.13.
What is the lowest forecasted price for ARCT Arcturus Therapeutics Holdings Inc.?
The lowest price target for ARCT is $9.00 from Yigal Nochomovitz at Citigroup, which represents a 26.2% increase from the current price of $7.13.
What is the overall ARCT consensus from analysts for Arcturus Therapeutics Holdings Inc.?
The overall analyst consensus for ARCT is bullish. Out of 21 Wall Street analysts, 8 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $21.50.
How accurate are ARCT stock price projections?
Stock price projections, including those for Arcturus Therapeutics Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 1:55 PM UTC